Gene editing
Showing 1 - 25 of 5,899
l Gene Editing Therapy for Cardiovascular Disease
Not yet recruiting
- Atherosclerotic Cardiovascular Disease
- +2 more
-
Auckland, New Zealand
- +2 more
Oct 31, 2023
Gene Editing as a Therapeutic Approach for Rett Syndrome
Recruiting
- Rett Syndrome
- Gene editing in vitro
-
Siena, ItalyUniversity of Siena
Feb 13, 2023
Viral Keratitis, Blindness Eye, Herpes Simplex Virus Infection Trial in Shanghai (BD111 Adult single group Dose)
Completed
- Viral Keratitis
- +3 more
- BD111 Adult single group Dose
-
Shanghai, Shanghai, ChinaEye & Ent Hospital of Fudan University
Aug 20, 2022
MPS I Trial in Oakland (SB-318)
Terminated
- MPS I
- SB-318
-
Oakland, CaliforniaUCSF Benioff Children's Hospital Oakland
Jan 6, 2023
Mucopolysaccharidosis II, MPS II Trial in United States (SB-913)
Terminated
- Mucopolysaccharidosis II
- MPS II
- SB-913
-
Oakland, California
- +4 more
Oct 21, 2022
Hemophilia B Trial in Washington (SB-FIX)
Terminated
- Hemophilia B
- SB-FIX
-
Washington, District of ColumbiaGeorgetown University Medical Center
Mar 8, 2022
(LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
Active, not recruiting
- Hemophilia B
- +2 more
- SB-318
- +2 more
-
Oakland, California
- +4 more
Jan 30, 2023
Exploiting Epigenome Editing in Kabuki Syndrome:New Route
Completed
- Kabuki Syndrome 1
- Intervention on primary cultured cells
-
Montpellier, Herault, FranceArnaud de villeneuve Hospital
Nov 30, 2020
Duchenne Muscular Dystrophy Trial in Worcester (CRD-TMH-001)
Enrolling by invitation
- Duchenne Muscular Dystrophy
-
Worcester, MassachusettsUMass Chan Medical School
Aug 22, 2022
Neovascular Age-related Macular Degeneration(nAMD) Trial in Shanghai, Tianjin (HG202)
Not yet recruiting
- Neovascular Age-related Macular Degeneration(nAMD)
- HG202
-
Shanghai, Shanghai, China
- +1 more
Sep 4, 2023
Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Hypercholesterolemia Trial in Auckland,
Recruiting
- Heterozygous Familial Hypercholesterolemia
- +2 more
-
Auckland, New Zealand
- +1 more
Aug 4, 2022
Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX)
Not yet recruiting
- Sickle Cell Disease
- Interview
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Mar 30, 2023
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma Trial in Nashville (CTX131)
Recruiting
- Clear Cell Renal Cell Carcinoma
- +4 more
- CTX131
-
Nashville, TennesseeResearch Site 1
Mar 21, 2023
Natural History of Autosomal Dominant Hearing Loss
Recruiting
- Hearing Loss
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 12, 2022
B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy Trial (CTX112)
Not yet recruiting
- B-cell Lymphoma
- +7 more
- CTX112
- (no location specified)
Dec 12, 2022
B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)
Active, not recruiting
- B-cell Lymphoma
- PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022
Gastrointestinal Epithelial Cancer, Gastrointestinal Tumors, Cancer of Gastrointestinal Tract Trial in Minneapolis
Recruiting
- Gastrointestinal Epithelial Cancer
- +10 more
- Cyclophosphamide
- +3 more
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Aug 20, 2021
Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies, Eye Diseases, Hereditary Trial in United States (EDIT-101)
Active, not recruiting
- Leber Congenital Amaurosis 10
- +6 more
-
Miami, Florida
- +4 more
Dec 2, 2022
Relapsed/Refractory Acute Myeloid Leukemia (AML) Trial in Dresden, Heidelberg (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated
Not yet recruiting
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion
- Gemtuzumab Ozogamicin
-
Dresden, Germany
- +1 more
Dec 20, 2022
Examining Knowledge, Attitudes, and Beliefs of Sickle Cell
Completed
- Sickle Cell Disease
-
Bethesda, MarylandNational Human Genome Research Institute (NHGRI)
Feb 5, 2021
Leukemia, Myeloid, Acute Trial (CD33KO-HSPC; CART33)
Not yet recruiting
- Leukemia, Myeloid, Acute
- CD33KO-HSPC; CART33
- (no location specified)
Jul 13, 2023
Major Depression Trial in Montpêllier (Blood sample for genetic purpose)
Completed
- Major Depression
- Blood sample for genetic purpose
-
Montpêllier, FranceUniversity Hospital
Dec 21, 2021
SCD Curative Therapies
Not yet recruiting
- Sickle Cell Disease
- +3 more
-
Washington, District of Columbia
- +4 more
Jun 28, 2022